Pharmacological intervention of Atorvastatin vs. Rosvastatin in patients with acute Ischemic Stroke (ARIS study) - ARIS study

Department of Stroke Treatment,Shonan Kamakura General Hospital0 个研究点目标入组 50 人开始时间: 2010年11月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with Japan Coma Scale (JCS) greater than 10 (Patients who cannot take foods orally) 2) Patients who have received atorvastatin or rosuvastatin before the observation period 3) Patients with familial hypercholesterolemia or secondary hyperlipidemia 4) Patients with the fasting TG level of more than 400 mg/dL 5) Patients with hypersensitivity to HMG-CoA reductase inhibitor(statin) 6) Patients within 3 months of stroke onset 7) Patients with active liver disease (ALT or AST levels more than 100IU/L, or a total bilirubin of more than 2.5 mg/dL) 8) Patients with renal dysfunction (the serum creatinine more than 2.0 mg/dL or Ccr<30mL/min/1.73 square meter) 9) Patients with the serum creatine kinase (CK) levels greater than 500IU/L 10) Patients on treatment with cyclosporine 11) Pregnant and potential pregnancy 12) Patients with hypothyroidism, hereditary myopathy (muscular dystrophy) or family history of hereditary myopathy, and drug-induced myopathy 13) Patients with drug abuse or alcoholism 14) Patients who are ineligible for any other reason in the opinion of the investigator

发起方

Department of Stroke Treatment,Shonan Kamakura General Hospital